CBLL · Ceribell, Inc.

Track CBLL — free

$24.39 -0.47 (-1.89%) At close · Sep 30

Russell 2000 member Rebalance outlook locked

Market Cap

$954.08M

38.38M

Volume · Sep 30 336.29K Avg daily vol (3M) 380.09K

Up next

Next earnings call

Nov 9, 2026 Est · unconfirmed · in 6 wks

Latest filing: 10-Q

filed Aug 10, 2026

Q2 2026 earnings call transcript

call held Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$101.96M

Trailing 12 months

Net income (TTM)

−$66.00M

Trailing 12 months

Revenue growth YoY

+32.5%

Year over year

Operating margin

-68.6%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-5.7%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$129.26M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+4.8%

Year over year · more shares

Price change (1Y)

+116.2%

Trailing year

Short interest

4.7%

Latest settlement · 6.1 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 10, 2026

Q2 FY26

TL;DR. CeriBell reported Q2 revenue of $28.1M, up 33% year-over-year, and raised full-year 2026 revenue guidance to $114–117M while securing new FDA 510(k) clearances for seizure-detection algorithms and next-generation hardware and refinancing its credit facility.

Bullish

+ Q2 revenue grew 33% year-over-year to $28.1M with same-store growth accelerating.
+ Raised full-year 2026 revenue guidance to $114–117M (up from $112–116M).
+ Gross margin expanded to 92% from 88%, with management confident in sustaining high-80% gross margins.
+ Received FDA 510(k) clearances for new Epileptiform Abnormality and Artifact Reduction algorithms, with rollout planned in Q3/Q4.
+ Secured new credit facility with up to $60M committed capital plus $25M uncommitted, extending repayment to 2031.
+ Received CMS NTAP for delirium monitoring effective October 1, 2026.

Bearish

− Net loss widened to $19.3M (loss of $0.51/share) from $13.6M (loss of $0.38/share) year-over-year.
− Operating expenses rose 37% to $45.9M, driven by IP litigation costs of $3.9M and higher stock-based compensation.
− Updated 2026 revenue guidance range still excludes material contributions from neonate and delirium products, deferring growth to 2027.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +20%

above

Price vs 50-day avg +9%

above

RSI (14) 55

neutral

MACD trend Negative

52-week position 95%

near high

Momentum

relative strength

Very Strong

1-month return −1%

trailing

6-month return +31%

trailing

YTD return +11%

this year

Relative strength +19%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $22 › 200d $20 — 50d above 200d

Institutional flow Flat

0% holders QoQ · +15 funds added

Insider flow Distributing

Net -$568.9K over 90 days · 100% sells

Short interest Falling

4.74% of float · ▼ -4.6% MoM · 6.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

122 holders — near 1-yr high, broad support

Squeeze score 69

elevated · 0–100

Fundamentals

Strong

Revenue growth +36%

Y/Y

Gross margin 88%

expanding

EPS growth +57%

Y/Y

Free cash flow $-41.6M

Quant / Vol

risk profile

High

Volatility 52%

annualized · 1-yr

Max drawdown −31%

past year

ATR 3.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Aug 10, 2026

Total revenue · full-year 2026 Initiated $114M – $117M

prior FY $89.06M midpoint +29.7% Y/Y

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+20% Bullish

Price vs 50-day avg

+9% Bullish

RSI (14)

55 Neutral

MACD trend

Negative Bearish

52-week position

95% Bullish

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $22 › 200d $20 — 50d above 200d

Institutional flow Flat

0% holders QoQ · +15 funds added

Insider flow Distributing

Net -$568.9K over 90 days · 100% sells

Short interest Falling

4.74% of float · ▼ -4.6% MoM · 6.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

122 holders — near 1-yr high, broad support

Price context

position in its 52-week range

Range low $11 Now $24 · 95% Range high $25

vs 200-day avg +20% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA (Non-GAAP) non-GAAP	-9.82M	Three months ended June 30, 2026 filing	—
EBITDA (Non-GAAP) non-GAAP	-19.74M	Three months ended June 30, 2026 filing	—
IP litigation matter non-GAAP	3.91M	Three months ended June 30, 2026 filing	—
Stock-based compensation non-GAAP	6M	Three months ended June 30, 2026 filing	—
total active accounts	712	Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CBLL Ceribell, Inc. this stock	$954.08M	+11.2%	+36.1%	—	4.7%
ABT Abbott Laboratories	$174.90B	-21.1%	+5.7%	28.1	1.1%
MDT Medtronic plc	$113.38B	-10.2%	+8.4%	21.8	1.3%
SYK Stryker Corp	$104.47B	-21.6%	+11.2%	28.2	2.0%
BSX Boston Scientific Corp	$63.59B	-54.2%	+12.5%	17.8	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

122

% held: 79.5%
Net QoQ: +641.1K sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

132

View

Short & Settlement

Short Interest Falling

Shares short

1.8M

Days to cover: 6.1d
Change: -88.0K sh

View

Short Volume

Short vol %

37%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $667
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

39.5%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$568.9K

Buyers / Sellers: 0 / 5

Buyers Sellers

View

Financials

Revenue (FY)

$89.1M

Net income (FY): $-53.4M
EPS diluted: $-1.46

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Aug 12, 2026
This year: 13

View

Proposed Sales

Value

$21.2K

Shares: 846
Filed: Sep 15, 2026

View

Exempt Offerings

Offering

$102.5M

Filed: Sep 29, 2022

View

Earnings & Events

Earnings Calls

Last call

Aug 12, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
CBLL	+3.3%	-0.8%	+31.3%	+1.7%	+11.2%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	+3.9%	-0.9%	+19.2%	+2.3%	-0.6%

Key facts CIK 1861107 CUSIP 15678C102 13F (30d) 2 filings 2 filers Visit website Investor relations

CBLL · Ceribell, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance